The prognostic role of albumin-bilirubin grade in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

OBJECTIVE: Our aim was to explore the prognostic role of baseline albumin-bilirubin levels (ALBI) on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: This retrospective study enrolled 58 cases of advanced NSCLC patients who received immune checkpoint inhibitor therapy from January 2019 to February 2022 in People's Hospital of Macheng. Patients were grouped according to the levels of baseline ALBI. The corresponding cut-off values were determined by receiver operating characteristic (ROC) curves. We also assessed potential predictive models for predicting efficacy of immunotherapy in advanced NSCLC. RESULTS: The median overall survival (OS) was not reached. The median OS of patients with PS = 1 after immunotherapy was significantly longer than that of PS = 2, which was NR vs. 6.67 months (HR=0.14, 95% CI: 0.05-0.46; p<0.01). The risk of death for patients with low ALBI (<-2.52) was significantly lower than that of patients with high ALBI (HR=0.28, 95% CI: 0.08-0.94; p=0.03). Univariate analysis showed that baseline ALBI and PS were factors significantly affecting OS in patients with advanced NSCLC after immunotherapy (p<0.05 for all). The combination of ALBI and PS showed a good predictive value in prognosis of these patients after immunotherapy (p<0.01). CONCLUSIONS: The baseline ALBI and PS may serve as prognostic factors for advanced NSCLC patients treated with immunotherapy. [ABSTRACT FROM AUTHOR]